Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468026 | 1.00 | PTPRB (1.00) | PTPRB | |
| SCHEMBL8282858 | 0.92 | PTPRB (0.85) | PTPRB | |
| SCHEMBL8523239 | 0.92 | PTPRB (0.85) | PTPRB | |
| SCHEMBL19775373 | 0.88 | PTPRB (0.78) | PTPRB | |
| SCHEMBL3617587 | 0.88 | PTPRB (0.78) | PTPRB | |
| SCHEMBL3617582 | 0.88 | PTPRB (0.78) | PTPRB | |
| SCHEMBL24318104 | 0.88 | PTPRB (0.78) | PTPRB | |
| SCHEMBL24318098 | 0.88 | PTPRB (0.78) | PTPRB | |
| SCHEMBL679272 | 0.88 | PTPRB (1.00) | PTPRB | |
| SCHEMBL468133 | 0.88 | PTPRB (1.00) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451279-B1 | BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC (US) | 2019-03-13 | — | — | EP | claimed |
| EP-2385763-B1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AERPIO THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | claimed |
| US-RE46592-E1 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | claimed |
| US-8946232-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | claimed |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-12-25 | — | — | US | claimed |
| US-8895563-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | claimed |
| US-8883832-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-8846685-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC. (US) | 2014-09-04 | — | — | US | claimed |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | SHALWITZ ROBERT (US) | 2014-06-26 | — | — | US | claimed |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-03-06 | — | — | US | claimed |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2013-12-12 | — | — | US | claimed |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-12-05 | — | — | US | claimed |
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20130023543-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | claimed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | claimed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | claimed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | claimed |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4414032-A2 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint Pharmaceuticals, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3977994-B1 | ACTIVATORS OF TIE-2 FOR USE IN TREATING INTRAOCULAR PRESSURE | EYEPOINT PHARMACEUTICALS INC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-20230139250-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | EYEPOINT PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220378750-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2022-12-01 | — | — | US | disclosed |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2022-09-01 | — | — | US | disclosed |
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2022-07-07 | — | — | US | disclosed |
| EP-3977994-A1 | ACTIVATORS OF TIE-2 FOR USE IN TREATING INTRAOCULAR PRESSURE | Aerpio Pharmaceuticals, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| EP-3352856-B1 | ACTIVATORS OF TIE-2 FOR USE IN TREATING INTRAOCULAR PRESSURE | AERPIO PHARMACEUTICALS INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210212998-A1 | Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof | EyePoint Pharmaceuticals, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-10952992-B2 | Methods of treating intraocular pressure with activators of Tie-2 | Aerpio Pharmaceuticals, Inc. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200397697-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | EyePoint Pharmaceuticals, Inc. | 2020-12-24 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2020-08-13 | — | — | US | disclosed |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | disclosed |
| US-20200108080-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-04-09 | — | — | US | disclosed |
| EP-3607821-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Aerpio Pharmaceuticals, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3556367-A1 | BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN THE TREATMENT OF CANCER OR METASTASIS | Aerpio Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2967066-B1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190231799-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2019-08-01 | — | — | US | disclosed |
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint Pharmaceuticals, Inc. | 2019-03-14 | — | — | US | disclosed |
| EP-2451279-B1 | BENZOSULFONAMIDE DERIVATIVES, COMPOSITIONS THEREOF, AND THEIR USE IN PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10220048-B2 | Compositions and methods for treating ocular diseases | AERPIO THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180251457-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-20180237429-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180237431-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180237430-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180221346-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2018-08-09 | — | — | US | disclosed |
| US-9949956-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2385763-B1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AERPIO THERAPEUTICS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-04-05 | — | — | US | disclosed |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-01-25 | — | — | US | disclosed |
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| EP-2624916-B1 | THIADIAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF OCULAR EDEMA | AERPIO THERAPEUTICS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20170319602-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-RE46592-E1 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9795594-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170079959-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | EyePoint, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20160374996-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2016-12-29 | — | — | US | disclosed |
| US-9440963-B2 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| US-9284285-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2967066-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160008327-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | EyePoint, Inc. | 2016-01-14 | — | — | US | disclosed |
| US-9174950-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9126958-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-9096555-B2 | Methods for treating vascular leak syndrome | AERPIO THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150210656-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2015-07-30 | — | — | US | disclosed |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2015-02-19 | — | — | US | disclosed |
| US-8946232-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-8895563-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2041102-B1 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8883832-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8846685-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145068-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AERPIO THERAPEUTICS INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2014-08-28 | — | — | US | disclosed |
| US-20140221666-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | SHALWITZ ROBERT (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2014-03-06 | — | — | US | disclosed |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2013-12-12 | — | — | US | disclosed |
| US-20130324558-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8569348-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2624916-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | Aerpio Therapeutics Inc. (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130023543-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8258311-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | AERPIO THERAPEUTICS INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2012-05-24 | — | — | US | disclosed |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EyePoint, Inc. | 2012-05-24 | — | — | US | disclosed |
| EP-2451279-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | Akebia Therapeutics Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2012047966-A2 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | AKEBIA THERAPEUTICS INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2011-11-03 | — | — | US | disclosed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100069448-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-03-18 | — | — | US | disclosed |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2010-01-21 | — | — | US | disclosed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622593-B2 | 4-{2-[2-(tert-Butoxycarbonyl)-3-phenylpropanamido]-2-(4-ethylthiazol-2-yl)ethyl}phenylsulfamic acid; anticarcinogenic, antitumor, antidiabrtic agent; angiogenesis inhibitor; sarcoid, syphilis, Paget's disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis/vitritis | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096140-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20120129847-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885 |
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20140242026-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | PTPRB 1445/4885 |
| US-20100016336-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20200108080-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885 |
| US-20140066458-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20170319602-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885 |
| US-20120128625-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | PTPRB 1445/4885 |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20190231799-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885 |
| US-20220211675-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | PTPRB 840/4885 |
| US-20140288134-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885 |
| US-10463650-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20130023543-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-10220048-B2 | Compositions and methods for treating ocular diseases | VEGFA, FLT4, AQP3 | PTPRB 2215/4885 |
| US-20140378445-A9 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | PTPRB 422/4885 |
| US-20200253936-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20180016245-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20140275103-A1 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20180237429-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885 |
| US-20140249100-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | EPCAM, CD44, CDH1 | PTPRB 1445/4885 |
| US-20180237431-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20170079959-A1 | METHODS OF TREATING INTRAOCULAR PRESSURE WITH ACTIVATORS OF TIE-2 | TIE1, TEK, VASP | PTPRB 1545/4885 |
| US-20190076405-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | PTPRB 841/4885 |
| US-20180237430-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20210212998-A1 | Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof | TIE1, PTGIR, PTGFR | PTPRB 1736/4885 |
| US-10952992-B2 | Methods of treating intraocular pressure with activators of Tie-2 | TIE1, TEK, VASP | PTPRB 1545/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20200397697-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | TIE1, TEK, KDR | PTPRB 704/4885 |
| US-20110268694-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20130331386-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20180251457-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20100069448-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20140179693-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, EPCAM | PTPRB 422/4885 |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20140221666-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20160008327-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASASIS OF CANCER CELLS | TSG101, MMP8, EPCAM | PTPRB 841/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20180037579-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885 |
| US-20160220540-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20180022741-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20230139250-A1 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | TIE1, TEK, KDR | PTPRB 704/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20220378750-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20180221346-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20150050277-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES | VEGFA, FLT4, AQP3 | PTPRB 2215/4885 |
| US-20180092883-A1 | PHOSPHATASE INHIBITORS FOR TREATING OCULAR DISEASES | PPM1G, PPM1F, PPM1A | PTPRB 62/4885 |
| US-20150210656-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.